A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
NCT05001087 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1900
Last updated 2025-02-27
Summary
The aim of this observational study is the creation of a national multiple myeloma registry to monitor the current routine clinical practice in Italy and describe the standard of care adopted for the diagnosis and treatment of patients with multiple myeloma in the different Italian hematology centers.
Conditions
Interventions
- OTHER
-
Observation
Not applicable-Observational study
Sponsors & Collaborators
- collaborator INDUSTRY
- collaborator INDUSTRY
-
Janssen-Cilag S.p.A.
collaborator INDUSTRY - collaborator INDUSTRY
- collaborator INDUSTRY
- collaborator INDUSTRY
-
Fondazione EMN Italy Onlus
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-16
- Primary Completion
- 2027-03-31
- Completion
- 2027-03-31
Countries
- Italy
Study Locations
More Related Trials
-
An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice
NCT02902900 ·Status: COMPLETED
-
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
NCT01241396 ·Status: COMPLETED
-
Immune Profiling in Multiple Myeloma
NCT04135079 ·Status: COMPLETED
-
European Myeloma Network (EMN) Sample Project
NCT06237803 ·Status: RECRUITING
-
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584 ·Status: RECRUITING
-
Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
NCT00358020 ·Status: COMPLETED ·Phase: PHASE2
-
Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma
NCT00327314 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05050097 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
NCT03848676 ·Status: COMPLETED
-
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies
NCT02997813 ·Status: COMPLETED
-
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
NCT00702247 ·Status: UNKNOWN ·Phase: PHASE2
-
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
NCT02164955 ·Status: COMPLETED
-
A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases
NCT05742217 ·Status: ACTIVE_NOT_RECRUITING
-
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
NCT02761187 ·Status: TERMINATED
-
Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD)
NCT03433365 ·Status: COMPLETED
-
MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis?
NCT03618212 ·Status: TERMINATED
-
A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)
NCT04135963 ·Status: COMPLETED
-
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
NCT03106324 ·Status: ACTIVE_NOT_RECRUITING
-
Stem Cell Translpantation in Multiple Myeloma
NCT05082675 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Myeloma Minimal Residual Disease
NCT02627261 ·Status: COMPLETED
-
Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
NCT07283224 ·Status: RECRUITING
-
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226 ·Status: COMPLETED
-
A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain
NCT02946333 ·Status: COMPLETED
-
Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients
NCT03409692 ·Status: COMPLETED